Ibogaine Clinical Trials in 2025: What's Registered

Quick answer

As of the 2025 registry review by Świeczkowski and colleagues, there were nine registered ibogaine clinical trials, mostly early-phase studies of pharmacokinetics, withdrawal and safety. Designs varied widely, cardiac monitoring was handled inconsistently, and there were no large late-phase trials. A listed trial is not proof of efficacy and not a way to get treatment. Ibogaine is Schedule I and not approved.

Definition

Definition: Świeczkowski D., Kwaśny A., Sadko K., Cubała W.J. (2025) in *Journal of Psychoactive Drugs* (doi: 10.1080/02791072.2025.2491385; PMID 40251723) is a cross-sectional landscape analysis titled *Not Losing Momentum: Cross-Sectional Insights into Ibogaine Clinical Trials*. Authors searched major registries (ClinicalTrials.gov, EU Clinical Trials / EU CTR, WHO ICTRP), deduplicated records, and analyzed nine ibogaine trials. They report early-phase dominance, methodological variability (fixed- vs ascending-dose designs, heterogeneous inclusion/exclusion and outcomes), emphasis on pharmacokinetics, withdrawal signals, and safety monitoring, and inconsistent handling of cardiovascular risk. Preliminary therapeutic interest is noted, but absence of large late-phase trials blocks definitive efficacy conclusions. A registry landscape map is not personal treatment access, not a cure claim, and not proof of physician-supervised IV ibogaine infusion (psychoactive intravenous ibogaine) efficacy. Ibogaine is U.S. Schedule I and not approved for any indication. QTc/cardiac safety themes remain central.

Short answer

Świeczkowski and colleagues’ 2025 Journal of Psychoactive Drugs cross-section of nine ibogaine trials finds early-phase work, design variability, and uneven cardiac-safety monitoring. Trial listings are not personal access and do not prove psychoactive IV ibogaine infusion efficacy. Large late-phase evidence is still missing. Schedule I; screen for QTc risk first.

Why this paper matters

Families Google “ibogaine clinical trials” and often infer:

> “Trials exist → I can enroll tomorrow → the drug is proven.”

This paper is the antidote: a registry cross-section that shows momentum and methodological immaturity. Pair with Texas/state research bills (/blog/texas-ibogaine-clinical-trials, /blog/ibogaine-state-research-bills-2026), noribogaine vs IV framing (/blog/noribogaine-trials-vs-iv-infusion), and thirty-year research honesty (/blog/thirty-years-ibogaine-research-review). Next steps: /safety-and-screening → /apply.

What was studied

Methods (plain language)

This is not a new dosing RCT. Investigators pulled registered ibogaine trials from major public registries, cleaned duplicates, and described what the active/listed programs were actually designed to measure. Cross-sectional registry reviews are excellent for mapping where science is, not for proving what works in your body. Registry presence can also lag, duplicate, or overstate “recruiting” status—always verify the live record.

Key findings (no hype)

Themes emphasized by the paper’s synthesis:

• Commercial interest and safety concerns both constrain clinical development of ibogaine for substance use disorders.
• Analyzed trials show considerable methodological variability (fixed-dose vs ascending-dose; diverse eligibility; divergent endpoints).
• Early-phase work dominates: pharmacokinetics, withdrawal-symptom reduction, and safety monitoring.
• Cardiovascular risk monitoring approaches differ meaningfully across protocols—an honesty gap families should notice.
• Preliminary signals of therapeutic interest exist in the broader literature the authors reference, but lack of large late-phase trials prevents definitive efficacy conclusions.
• Authors call for a standardized clinical framework and note that lessons from classical psychedelics and MDMA research (blinding, expectancy bias) could improve design quality.

Honest reading: “Not losing momentum” describes research activity—not guaranteed consumer access, not regulatory approval, and not a cure rate.

Limits and confounders

Trial landscape ≠ personal access

Critical safety distinctions:

1. Seeing a ClinicalTrials.gov row ≠ enrollment tomorrow. Geography, phase, sponsor, inclusion criteria, and cardiac screens block most readers.
2. Research momentum ≠ product approval. Ibogaine remains Schedule I in the U.S. and not approved for any indication for any indication (/blog/is-ibogaine-legal-us).
3. Observational clinic programs abroad ≠ registered late-phase RCTs. Do not swap labels.
4. State research bills / funding interest (/blog/texas-ibogaine-clinical-trials) may expand future trials—they do not create a consumer “cure product” today.
5. IV ibogaine infusion as described on this site questions still require route honesty and medical screening—trial headlines do not waive ECG.

Route honesty: oral ≠ psychoactive IV

Most historical and many ongoing human ibogaine programs use oral (or formulation-unspecified) dosing. A registry landscape that catalogs early SUD trials does not automatically validate physician-supervised psychoactive intravenous delivery. Support IV (e.g., fluids, magnesium in some oral protocols) is still not psychoactive IV (/blog/ibogaine-oral-vs-iv, /blog/stanford-ibogaine-mistic, /blog/magnesium-ibogaine-cardiac-protocol). Overview: /what-is-ibogaine-infusion.

Cardiac safety context — what the landscape paper reinforces

The authors flag inconsistent cardiovascular-safety handling across trials. That maps directly onto family due diligence:

Deep dives: /blog/knuijver-2021-ibogaine-qtc-safety, /blog/ibogaine-cardiovascular-complications-review, /blog/ibogaine-setting-factors-safety-review-2023, /blog/ibogaine-ecg-pre-infusion-checklist, /blog/ibogaine-telemetry-acls-monitoring, /blog/ibogaine-contraindications.

What this does NOT prove for IV ibogaine infusion

No cure claims. Anti-addictive evidence across the field remains incomplete pending rigorous late-phase work (see also Köck et al. thirty-year narrative caution: /blog/thirty-years-ibogaine-research-review).

Next steps

If trial headlines made you hopeful, keep the hope and the homework. Learn cardiac and psychiatric screening expectations at /safety-and-screening, then /apply only if exploring physician-supervised IV ibogaine infusion questions with eyes open. Entity: /what-is-ibogaine-infusion.

FAQ

What is the “Not Losing Momentum” paper? A 2025 *Journal of Psychoactive Drugs* cross-sectional analysis of nine registered ibogaine clinical trials (doi 10.1080/02791072.2025.2491385).

Does a listed trial mean I can get treatment next week? No. Landscape ≠ personal access. Eligibility, location, phase, and legal status usually block casual enrollment.

Are most trials late-phase efficacy proof? No—authors describe early-phase dominance focused on PK, withdrawal, and safety.

What safety theme stands out? Inconsistent attention to **cardiovascular / QTc** risk monitoring across protocols.

Does this prove IV ibogaine infusion works? No. It maps trial design variability; it is not an efficacy RCT for psychoactive IV dosing.

Is ibogaine approved because trials exist? No. Schedule I in the U.S.; not approved for any indication.

Should families still demand ECG/telemetry? Yes (/blog/ibogaine-ecg-pre-infusion-checklist, /safety-and-screening).

Where should screening start? /safety-and-screening, then /apply if appropriate.

Medical disclaimer

Educational research synopsis only—not medical, psychiatric, or legal advice, and not a guarantee of outcomes. Ibogaine can prolong the QTc interval and has been associated with serious cardiac events including torsades de pointes and death in some contexts. Ibogaine is Schedule I in the United States and is not approved for any indication. Our IV ibogaine programs in Mexico and Gabon are not approved U.S. clinics. Next steps: /safety-and-screening, then /apply.

Świeczkowski et al. 2025 is a clinical-trial landscape cross-section—not personal access, not a cure claim, and not psychoactive IV ibogaine efficacy proof.

Sources (selected)

1. Świeczkowski D., Kwaśny A., Sadko K., Cubała W.J. Not Losing Momentum: Cross-Sectional Insights into Ibogaine Clinical Trials. *J Psychoactive Drugs*. 2025. doi: 10.1080/02791072.2025.2491385. PMID: 40251723.
2. Knuijver T. et al. *Addiction*. 2021. doi: 10.1111/add.15448.
3. Brunt T.M. *Addiction*. 2026. doi: 10.1111/add.70319.
4. Köck P. et al. Thirty Years of Ibogaine Research. *J Clin Psychopharmacol*. 2025. doi: 10.1097/jcp.0000000000002197.
5. 21 CFR 1308.11 — ibogaine Schedule I (United States).

Are there any ibogaine clinical trials?

Yes, but only a few. The review searched ClinicalTrials.gov, the EU clinical trials registers and the WHO ICTRP, removed duplicates, and analyzed nine ibogaine trials. That is a small field. It is not dozens of large programs.

What are ibogaine trials testing?

Most of them are early-phase. They focus on:

• Pharmacokinetics: how ibogaine is absorbed, metabolized and cleared.
• Withdrawal: whether opioid withdrawal symptoms change.
• Safety monitoring: especially of heart rhythm.

Designs differ, too. Some use a fixed dose and others an ascending dose, with different eligibility rules and outcome measures. That variability makes it hard to combine results into one answer about whether it works.

Is there a phase 3 ibogaine trial?

The review found no large late-phase trials, and the authors say that absence prevents definitive conclusions about efficacy. Treat any claim that ibogaine is "proven in trials" with caution.

How do I join an ibogaine clinical trial?

Check the live record on the registry. Status can lag, and a trial listed as recruiting may have closed. Each trial has strict criteria, often including ECG and QTc limits, and many people do not qualify. Enrollment goes through the research team, not through a treatment clinic. State-level research efforts are covered in Texas ibogaine clinical trials and state research bills in 2026.

How do trials handle ibogaine's heart risk?

Inconsistently, according to the review. Protocols differed in how they monitored cardiovascular risk. Families should notice that gap. Ibogaine can prolong the QTc interval; see the Knuijver 2021 QTc study and our ibogaine heart-risk review. Any setting, research or clinical, should include ECG screening and continuous telemetry.

Do trials mean ibogaine will be approved soon?

No one can say. Ongoing research is not approval. Ibogaine remains Schedule I in the United States and is not approved for any indication. The authors call for a standardized clinical framework and better blinding and expectancy controls, drawing lessons from psilocybin and MDMA research. For how the evidence has developed, see thirty years of ibogaine research (/blog/thirty-years-ibogaine-research-review).

What if I can't get into a trial?

Some people look at programs abroad. Programs serving U.S. patients operate outside the U.S., with intake locations including Mexico and Gabon. Those are not clinical trials and are not approved U.S. clinics. Apply the same cardiac screening standards. See how to choose an ibogaine clinic.

Next step: Read safety and screening (/safety-and-screening), then apply (/apply).